StonvexLoading…
StonvexStonvexStonvexCore line items from AGL's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.42B | $5.93B | $4.36B | $2.93B |
Operating Income | $4.00M | $-463.24M | $-269.41M | $-138.14M |
Net Income | $48.92M | $-391.35M | $-202.47M | $-92.26M |
EPS (Diluted) | $2.94 | $-0.98 | $-0.52 | $-0.25 |
Total Assets | $1.50B | $1.27B | $1.60B | $1.71B |
Total Liabilities | $1.32B | $1.14B | $1.29B | $1.30B |
Cash & Equivalents | $139.99M | $173.71M | $171.68M | $171.42M |
Free Cash Flow OCF − CapEx | $20.63M | $-119.00M | $-95.50M | $-74.17M |
Shares Outstanding | 16.61M | 16.59M | 414.57M | 414.28M |